ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer
Open Access
- 1 May 2020
- journal article
- review article
- Published by Elsevier BV in ESMO Open
- Vol. 5 (Suppl 3), e000793
- https://doi.org/10.1136/esmoopen-2020-000793
Abstract
The global preparedness and response to the rapid escalation to severe acute respiratory syndrome coronavirus (SARS-CoV)-2-related disease (COVID-19) to a pandemic proportion has demanded the formulation of a reliable, useful and evidence-based mechanism for health services prioritisation, to achieve the highest quality standards of care to all patients. The prioritisation of high value cancer interventions must be embedded in the agenda for the pandemic response, ensuring that no inconsistency or discrepancy emerge in the health planning processes. The aim of this work is to organise health interventions for breast cancer management and research in a tiered framework (high, medium, low value), formulating a scheme of prioritisation per clinical cogency and intrinsic value or magnitude of benefit. The public health tools and schemes for priority setting in oncology have been used as models, aspiring to capture clinical urgency, value in healthcare, community goals and fairness, while respecting the principles of benevolence, non-maleficence, autonomy and justice. We discuss the priority health interventions across the cancer continuum, giving a perspective on the role and meaning to maintain some services (undeferrable) while temporarily abrogate some others (deferrable). Considerations for implementation and the essential link to pre-existing health services, especially primary healthcare, are addressed, outlining a framework for the development of effective and functional services, such as telemedicine. The discussion covers the theme of health systems strategising, and why oncology care, in particular breast cancer care, should be maintained in parallel to pandemic control measures, providing a pragmatic clinical model within the broader context of public healthcare schemes.This publication has 30 references indexed in Scilit:
- ESMO-Magnitude of Clinical Benefit Scale version 1.1Annals of Oncology, 2017
- Determinants of Last-line Treatment in Metastatic Breast CancerClinical Breast Cancer, 2017
- Mastectomy skin flap necrosis: challenges and solutionsBreast Cancer: Targets and Therapy, 2017
- Abstract P4-21-17: BELIS: Safety and tolerability of at home administration of trastuzumab (Herceptin®) subcutaneous for the treatment of patients with HER2-positive early breast cancerCancer Research, 2017
- Breast cancerThe Lancet, 2016
- Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trialThe Lancet Oncology, 2015
- Delay in Breast Cancer: Implications for Stage at Diagnosis and SurvivalFrontiers in Public Health, 2014
- Effects of multidisciplinary team working on breast cancer survival: retrospective, comparative, interventional cohort study of 13 722 womenBMJ, 2012
- Prognosis After Ipsilateral Breast Tumor Recurrence and Locoregional Recurrences in Patients Treated by Breast-Conserving Therapy in Five National Surgical Adjuvant Breast and Bowel Project Protocols of Node-Negative Breast CancerJournal of Clinical Oncology, 2009
- Adjuvant therapy after excision and radiation of isolated postmastectomy locoregional breast cancer recurrence: definitive results of a phase III randomized trial (SAKK 23/82) comparing tamoxifen with observationAnnals of Oncology, 2003